Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603641 · ClinicalTrials.gov registry record · Phase 3
BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
NCT01603641: Completed Phase 3 study, sponsored by Allergan.
NCT01603641 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 370 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603641, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric lower limb spasticity.
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period.
Interventions
- BIOLOGICAL Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2012-11-05 |
| Est. Completion | 2018-08-25 |
| Phase | Phase 3 |
What the finished NCT01603641 record still lists
NCT01603641 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxin Type A is the first listed.
NCT01603641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01603641 about?
NCT01603641 is a clinical study titled "BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity". This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric lower limb spasticity.
What is the current status of trial NCT01603641?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2012-11-05. Estimated completion is 2018-08-25.
What interventions are being tested in trial NCT01603641?
The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01603641?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01603641's enrollment target sits among peer trials
370 993rd of 2000 higher than 1,006 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI